FDA grants digital therapeutic for Alzheimer's symptoms Breakthrough Device designation
Mobi Health News
AUGUST 23, 2018
Dthera Sciences, a San Diego-based developer of clinical and consumer digital therapeutics for individuals with neurodegenerative conditions, announced today that its development stage intervention, DTHR-ALZ, has been granted Breakthrough Device designation by the FDA.
Let's personalize your content